About
Preventing Breast Cancer Recurrence
ResCure Pharma is developing novel platform technology for discovery and development of therapies for breast cancer recurrence. Approximately 20% of breast cancer patients are at risk of breast cancer recurrence 5-20 years after initial treatment. Recurrence can occur locally (in the treated breast or near the mastectomy scar) or appear as a metastatic disease in distant organs. To date there is no treatment to eradicate metastatic disease. Therefore, it is essential to develop new therapeutic approaches to confront metastatic disease before it emerges. ResCure is in the process of initial validation of potential compounds discovered by the company for the prevention and treatment of metastatic breast cancer recurrence.
Identity
| Name | ResCure Pharma |
|---|---|
| Slug | rescure-pharma |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoImosJILDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Aug 2018 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Haifa |
| HQ address | Haifa, Israel |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}